Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Interest Expenses (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Interest Expenses readings, the most recent being $830000.0 for Q1 2026.

  • On a quarterly basis, Interest Expenses fell 18.39% to $830000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $3.6 million, a 19.51% decrease, with the full-year FY2025 number at $3.8 million, down 17.83% from a year prior.
  • Interest Expenses hit $830000.0 in Q1 2026 for Atara Biotherapeutics, down from $894000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.4 million in Q3 2023 to a low of $4000.0 in Q1 2022.
  • Median Interest Expenses over the past 5 years was $1.0 million (2024), compared with a mean of $876176.5.
  • Biggest five-year swings in Interest Expenses: surged 33300.0% in 2023 and later fell 23.16% in 2025.
  • Atara Biotherapeutics' Interest Expenses stood at $117000.0 in 2022, then surged by 905.13% to $1.2 million in 2023, then dropped by 13.52% to $1.0 million in 2024, then fell by 12.09% to $894000.0 in 2025, then dropped by 7.16% to $830000.0 in 2026.
  • The last three reported values for Interest Expenses were $830000.0 (Q1 2026), $894000.0 (Q4 2025), and $909000.0 (Q3 2025) per Business Quant data.